Lupin Limited

500257

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:44 2025-06-20 am EDT			5-day change	1st Jan Change
1,946.75 ^INR	+0.74%		-2.68%	-17.19%

Jun. 16	Lupin, Sino Universal Pharmaceuticals Sign License, Supply Agreement For Tiotropium DPI In China	RE
Jun. 16	Indian Indices Gain as Easing Middle East Tensions Lift Sentiment	MT

Lupin Honeywell Move Forward Jointly With Plans For HFO Technology In Inhalers

Published on 05/20/2025 at 02:46

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Lupin Limited

Lupin, Sino Universal Pharmaceuticals Sign License, Supply Agreement For Tiotropium DPI In China	Jun. 16	RE
Indian Indices Gain as Easing Middle East Tensions Lift Sentiment	Jun. 16	MT
Lupin Signs Pact to Market Tiotropium Dry Powder Inhaler in China	Jun. 16	MT
Lupin Gets US FDA's Tentative Nod for Oxcarbazepine Extended-Release Tablets	Jun. 08	MT
Lupin Limited Receives Tentative Approval from U.S. FDA for Oxcarbazepine ER Tablets	Jun. 07	CI
Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 Inhibitor) at the American Society of Clinical Oncology - Annual Meeting 2025	May. 27	CI
Lupin to Present Early Trial Data on Cancer Drug LNP7457 at ASCO 2025	May. 26	MT
Lupin Limited Enters into License and Supply Agreement with SteinCares	May. 26	CI
Lupin Honeywell Move Forward Jointly With Plans For HFO Technology In Inhalers	May. 20	RE
Punita Kumar-Sinha Express Her Intention to Not Renew Her Tenure as Independent Director of the Company with Effect from Close of Business Hours of August 11, 2025	May. 19	CI
Lupin Limited - Shareholder/Analyst Call	May. 16
Lupin Seeks Acquisition Opportunities	May. 15	CI
Waters Corp's India business boosted by rush for weight-loss drugs	May. 15	RE
Global Pharma Major Lupin Limited Appoints Punita Lal as Non-Executive, Independent Additional Director	May. 15	CI
Lupin Limited Receives Approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 10 Mg, 15 Mg	May. 15	CI
Lupin Limited Reports Earnings Results for the Full Year Ended March 31, 2025	May. 14	CI
Lupin Launches Tolvaptan Tablets In U.S.	May. 13	RE
Lupin Limited Launches Tolvaptan Tablets in the U.S. with 180-Day Exclusivity	May. 13	CI
Pharma stocks recover from initial shock of Trump's drug pricing order	May. 12	RE
Pharma stocks recover from initial shock of Trump's drug pricing order	May. 12	RE
Donald Trump deals another blow to Big Pharma	May. 12
Indian pharma stocks fall as Trump moves to cut U.S. drug prices	May. 12	RE
Lupin Wins US FDA Approval for HIV Drug Raltegravir With 180-Day Market Exclusivity	May. 08	MT
Lupin Receives U.S. FDA Approval For Raltegravir Tablets USP, 600 Mg	May. 08	RE
Lupin Limited Receives Approval from U.S. FDA for Raltegravir Tablets USP, 600 Mg	May. 08	CI

Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).

Employees

19,210

Sector

Pharmaceuticals

Calendar

Jun. 24 - Nuvama Specialty Chemicals and Healthcare Investor Conference

More about the company